JP2004523566A - アンホテリシンｂ水性組成物 - Google Patents
アンホテリシンｂ水性組成物 Download PDFInfo
- Publication number
- JP2004523566A JP2004523566A JP2002569158A JP2002569158A JP2004523566A JP 2004523566 A JP2004523566 A JP 2004523566A JP 2002569158 A JP2002569158 A JP 2002569158A JP 2002569158 A JP2002569158 A JP 2002569158A JP 2004523566 A JP2004523566 A JP 2004523566A
- Authority
- JP
- Japan
- Prior art keywords
- amphotericin
- sodium chloride
- phospholipids
- composition
- dimethyl sulfoxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 title claims abstract description 155
- 229960003942 amphotericin b Drugs 0.000 title claims abstract description 155
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 title claims abstract description 149
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 197
- 239000011780 sodium chloride Substances 0.000 claims abstract description 101
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 95
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 94
- 239000002904 solvent Substances 0.000 claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 238000007911 parenteral administration Methods 0.000 claims abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 239000000725 suspension Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 231100000053 low toxicity Toxicity 0.000 claims description 26
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 25
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 25
- 239000008346 aqueous phase Substances 0.000 claims description 22
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 22
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- 239000003365 glass fiber Substances 0.000 claims description 19
- 231100000252 nontoxic Toxicity 0.000 claims description 14
- 230000003000 nontoxic effect Effects 0.000 claims description 14
- 239000008363 phosphate buffer Substances 0.000 claims description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000002953 phosphate buffered saline Substances 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 6
- 231100000331 toxic Toxicity 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- QLNOOKSBAYIHQI-SKZICHJRSA-M sodium;2,3-dihydroxypropyl [(2r)-2,3-di(tetradecanoyloxy)propyl] phosphate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC QLNOOKSBAYIHQI-SKZICHJRSA-M 0.000 claims description 3
- 229930183010 Amphotericin Natural products 0.000 claims description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 2
- 229940009444 amphotericin Drugs 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 abstract description 2
- 208000031888 Mycoses Diseases 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000000047 product Substances 0.000 description 21
- 150000002632 lipids Chemical class 0.000 description 17
- -1 amphotericin B lipid Chemical class 0.000 description 16
- 239000010408 film Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000000265 homogenisation Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 239000007900 aqueous suspension Substances 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 5
- 230000005587 bubbling Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN217MU2001 IN188924B (OSRAM) | 2001-03-01 | 2001-03-01 | |
| PCT/IN2001/000040 WO2002069983A1 (en) | 2001-03-01 | 2001-03-16 | Amphotericin b aqueous composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004523566A true JP2004523566A (ja) | 2004-08-05 |
Family
ID=11097223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569158A Pending JP2004523566A (ja) | 2001-03-01 | 2001-03-16 | アンホテリシンｂ水性組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040137049A1 (OSRAM) |
| EP (1) | EP1368041B1 (OSRAM) |
| JP (1) | JP2004523566A (OSRAM) |
| KR (1) | KR100810067B1 (OSRAM) |
| CN (1) | CN1255114C (OSRAM) |
| AT (1) | ATE274913T1 (OSRAM) |
| AU (1) | AU2001250643B2 (OSRAM) |
| BG (1) | BG108188A (OSRAM) |
| BR (1) | BR0116922A (OSRAM) |
| CA (1) | CA2438847A1 (OSRAM) |
| CZ (1) | CZ20032264A3 (OSRAM) |
| DE (1) | DE60105322T2 (OSRAM) |
| DK (1) | DK1368041T3 (OSRAM) |
| EA (1) | EA006241B1 (OSRAM) |
| ES (1) | ES2227172T3 (OSRAM) |
| IN (1) | IN188924B (OSRAM) |
| MX (1) | MXPA03007777A (OSRAM) |
| NZ (1) | NZ528281A (OSRAM) |
| PT (1) | PT1368041E (OSRAM) |
| SK (1) | SK10742003A3 (OSRAM) |
| WO (1) | WO2002069983A1 (OSRAM) |
| YU (1) | YU75403A (OSRAM) |
| ZA (1) | ZA200307307B (OSRAM) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006069929A (ja) * | 2004-08-31 | 2006-03-16 | Konica Minolta Medical & Graphic Inc | 真菌症治療製剤およびその製造方法 |
| CN108309955A (zh) * | 2018-04-27 | 2018-07-24 | 武昌理工学院 | 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| KR20070058608A (ko) * | 2004-09-13 | 2007-06-08 | 바라트 쎄럼스 앤드 백신스 리미티드 | 항미생물 방부 효능을 갖는 정맥 내 투여를 위한 안정한에멀젼 조성물 |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| CN100418536C (zh) * | 2005-04-06 | 2008-09-17 | 河南省眼科研究所 | 一种用于眼科的抗真菌药物组合物 |
| ATE481963T1 (de) | 2006-05-30 | 2010-10-15 | Intarcia Therapeutics Inc | Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem |
| AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| MX2009011123A (es) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
| DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
| KR102093612B1 (ko) | 2009-09-28 | 2020-03-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
| KR101629521B1 (ko) * | 2010-03-16 | 2016-06-13 | 우석대학교 산학협력단 | 난용성 약물 가용화 및 생체막 투과증진을 위한 알코올성 수상을 내상으로 하는 리포좀, 리포좀 조성물 및 리포좀의 제조방법 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| CN102525921B (zh) * | 2012-02-06 | 2013-08-07 | 西安力邦制药有限公司 | 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法 |
| WO2013142184A1 (en) * | 2012-03-19 | 2013-09-26 | Yale University | Antimicrobial compositions and methods |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| KR102650751B1 (ko) | 2015-06-03 | 2024-03-22 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
| EP3222324B1 (en) | 2016-03-23 | 2020-05-13 | Wayne State University | Valproate as a topical anti-fungal treatment |
| CA3024479A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| MX2019008006A (es) | 2017-01-03 | 2019-08-29 | Intarcia Therapeutics Inc | Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco. |
| CN108344811A (zh) * | 2017-01-24 | 2018-07-31 | 北京泰德制药股份有限公司 | 一种注射用脂质体中有机溶剂残留的检测方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03169808A (ja) * | 1989-09-14 | 1991-07-23 | Medgenix Group Sa | 新しい脂質微粒子の製法 |
| JPH09241168A (ja) * | 1996-03-04 | 1997-09-16 | Nof Corp | アンホテリシンｂ運搬体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338736C (fr) * | 1986-12-05 | 1996-11-26 | Roger Baurain | Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation |
| US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
| US5100662A (en) * | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
| US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US6180136B1 (en) * | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
-
2001
- 2001-03-01 IN IN217MU2001 patent/IN188924B/en unknown
- 2001-03-16 CN CNB018231632A patent/CN1255114C/zh not_active Expired - Fee Related
- 2001-03-16 WO PCT/IN2001/000040 patent/WO2002069983A1/en not_active Ceased
- 2001-03-16 ES ES01923963T patent/ES2227172T3/es not_active Expired - Lifetime
- 2001-03-16 PT PT01923963T patent/PT1368041E/pt unknown
- 2001-03-16 CA CA002438847A patent/CA2438847A1/en not_active Abandoned
- 2001-03-16 KR KR1020037011489A patent/KR100810067B1/ko not_active Expired - Fee Related
- 2001-03-16 EA EA200300948A patent/EA006241B1/ru not_active IP Right Cessation
- 2001-03-16 YU YU75403A patent/YU75403A/sh unknown
- 2001-03-16 EP EP01923963A patent/EP1368041B1/en not_active Expired - Lifetime
- 2001-03-16 AT AT01923963T patent/ATE274913T1/de not_active IP Right Cessation
- 2001-03-16 JP JP2002569158A patent/JP2004523566A/ja active Pending
- 2001-03-16 MX MXPA03007777A patent/MXPA03007777A/es active IP Right Grant
- 2001-03-16 NZ NZ528281A patent/NZ528281A/en not_active IP Right Cessation
- 2001-03-16 AU AU2001250643A patent/AU2001250643B2/en not_active Ceased
- 2001-03-16 DE DE60105322T patent/DE60105322T2/de not_active Expired - Lifetime
- 2001-03-16 US US10/469,624 patent/US20040137049A1/en not_active Abandoned
- 2001-03-16 CZ CZ20032264A patent/CZ20032264A3/cs unknown
- 2001-03-16 SK SK1074-2003A patent/SK10742003A3/sk unknown
- 2001-03-16 BR BR0116922-0A patent/BR0116922A/pt active Search and Examination
- 2001-03-16 DK DK01923963T patent/DK1368041T3/da active
-
2003
- 2003-09-18 ZA ZA200307307A patent/ZA200307307B/en unknown
- 2003-09-23 BG BG108188A patent/BG108188A/bg unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03169808A (ja) * | 1989-09-14 | 1991-07-23 | Medgenix Group Sa | 新しい脂質微粒子の製法 |
| JPH09241168A (ja) * | 1996-03-04 | 1997-09-16 | Nof Corp | アンホテリシンｂ運搬体 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006069929A (ja) * | 2004-08-31 | 2006-03-16 | Konica Minolta Medical & Graphic Inc | 真菌症治療製剤およびその製造方法 |
| CN108309955A (zh) * | 2018-04-27 | 2018-07-24 | 武昌理工学院 | 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60105322D1 (de) | 2004-10-07 |
| EA200300948A1 (ru) | 2004-04-29 |
| CN1505519A (zh) | 2004-06-16 |
| EA006241B1 (ru) | 2005-10-27 |
| KR100810067B1 (ko) | 2008-03-05 |
| CN1255114C (zh) | 2006-05-10 |
| AU2001250643B2 (en) | 2007-03-22 |
| ATE274913T1 (de) | 2004-09-15 |
| EP1368041A1 (en) | 2003-12-10 |
| CZ20032264A3 (cs) | 2003-12-17 |
| DK1368041T3 (da) | 2005-01-17 |
| CA2438847A1 (en) | 2002-09-12 |
| KR20040018337A (ko) | 2004-03-03 |
| MXPA03007777A (es) | 2003-12-08 |
| NZ528281A (en) | 2006-11-30 |
| EP1368041B1 (en) | 2004-09-01 |
| DE60105322T2 (de) | 2005-09-15 |
| US20040137049A1 (en) | 2004-07-15 |
| SK10742003A3 (sk) | 2004-01-08 |
| YU75403A (sh) | 2006-05-25 |
| BR0116922A (pt) | 2004-04-27 |
| BG108188A (bg) | 2004-09-30 |
| PT1368041E (pt) | 2005-01-31 |
| WO2002069983A1 (en) | 2002-09-12 |
| ES2227172T3 (es) | 2005-04-01 |
| IN188924B (OSRAM) | 2002-11-23 |
| ZA200307307B (en) | 2004-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004523566A (ja) | アンホテリシンｂ水性組成物 | |
| AU2001250643A1 (en) | Amphotericin B aqueous composition | |
| US5100591A (en) | Process for preparing lipid microparticles | |
| JP2528153B2 (ja) | リポソ―ム製剤および抗生物質 | |
| EP1259225B1 (en) | Process of dehydration/rehydration for making liposomes | |
| US6406713B1 (en) | Methods of preparing low-toxicity drug-lipid complexes | |
| JP3267611B2 (ja) | リポソーム−ポリエンプレリポソーム粉末とその製造方法 | |
| FI102724B (fi) | Menetelmä bioaktiivisesta aineesta ja lipidistä koostuvan kompleksin v almistamiseksi | |
| HUT73808A (en) | Injectable liposomatic pharmaceutical compositions | |
| Khatib et al. | Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation | |
| ITMI940790A1 (it) | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base | |
| JP2758297B2 (ja) | リポソーム調製物 | |
| WO1996022764A1 (en) | Liposomes containing a corticosteroid | |
| FI104951B (fi) | Menetelmä parenteraalisesti annettavan liposomikoostumuksen valmistamiseksi | |
| JPH06321772A (ja) | 水性リポソーム系およびそのリポソーム系の調製法 | |
| US20060030578A1 (en) | Pharmaceutically active lipid based formulation of irinotecan | |
| CN110974937B (zh) | 一种多粘菌素e脂质体及其制备方法和应用 | |
| NL2036378B1 (en) | Preparation of liposomes | |
| CN119770430A (zh) | 一种槲皮素脂质体的制备方法 | |
| CN119486716A (zh) | 新型度格列汀制剂及其制备方法 | |
| MXPA97005592A (en) | Pharmaceutical compositions containing corticosteroids and preparation of mys |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110728 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120126 |